Level Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Level Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$394K	Hold	6,880	–	–	0.16%	48
2026 Q1	$389K	Hold	6,880	–	–	0.18%	41
2025 Q4	$409K	Sell	6,880 -2,180	-24%	-$119K	0.21%	36
2025 Q3	$491K	Hold	9,060	–	–	0.26%	32
2025 Q2	$498K	Hold	9,060	–	–	0.29%	31
2025 Q1	$640K	Sell	9,060 -483	-5%	-$32.5K	0.42%	22
2024 Q4	$627K	Buy	+9,543	New	+$639K	0.44%	24

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Level Wealth Management's BMRN Position: Q2 2026 in Review

Level Wealth Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 6,880 shares worth $394K. The position accounts for 0.16% of the portfolio, ranked #48.

Level Wealth Management first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $640K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Level Wealth Management held 6,880 shares of BioMarin Pharmaceuticals worth $394K as of Q2 2026.
Level Wealth Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.16% of Level Wealth Management's portfolio in Q2 2026, its #48 holding.
Level Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Level Wealth Management's BioMarin Pharmaceuticals position peaked at $640K in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Level Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.